Search

4-Phenylfentanyl

thiophenes and thiazoles are more potent still, as they are closer bioisosteres to the 4-carbomethoxy group of carfentanil. … 4-Phenylfentanyl is a sythetic opioid derived from fentanyl. 4-Phenylfentanyl is around 8x the potency of fentanyl in analgesic tests on animals, but more complex 4-heteroaryl derivatives such as substituted

Teclozan

Teclozan is an antiprotozoal agent employed typically as a therapy to treat protozoan infections.

Brasofensine

In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230.

Fluciclatide

Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.

TD-0903

TD-0903 was investigated in clinical trials for its potential to treat acute lung injury (ALI) associated with COVID-19, including NCT04350736, NCT05091723 (a pharmacokinetics study in healthy participants

Vabametkib

Vabametkib has a monoisotopic molecular weight of 566.3 Da.

Fleroxacin

Fleroxacin is a broad-spectrum antimicrobial fluoroquinolone. It strongly inhibits the DNA-supercoiling activity of DNA gyrase. Fleroxacin is not an inhibitor of CYP1A2.

Etranacogene dezaparvovec

[L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44156] Etranacogene dezaparvovec was approved by the FDA in November 2022 for the treatment of select patients with hemophilia B, becoming the first gene therapy approved for this indication.

Hydrocortisone aceponate

HLX70

HLX70, a recombinant humanized anti-S protein monoclonal antibody intended for intravenous infusion, was under investigation in clinical trials NCT05429385 and NCT04561076 to evaluate its safety and pharmacokinetics